Momenta Pharmaceuticals
Cambridge
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans. This results in a diversified product pipeline of complex generic, follow-on biologic and novel drugs. The Company's two most advanced complex generic product candidates target marketed products, which were originally approved by the United States Food and Drug Administration as New Drug Applications. M-Enoxaparin is designed to be a generic version of Lovenox (enoxaparin sodium injection), a low-molecular weight heparin used to prevent and treat deep vein thrombosis. Its second major generic product candidate is M356, a generic version of Copaxone (glatiramer acetate injection), a drug that is indicated for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 501 – 1,000
- Estimated revenue: $100K – $500K
- Total funding: $88.5M
- Funding stage: M&A
- Last round: Post-IPO Equity (Sep 2009)
- Ticker: nasdaq:MNTA
- Website: momentapharma.com
- Phone: (617)621-0431
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/momenta-pharmaceuticals-2660542 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.